Skip to main content

Table 2 Incidence (per 100 person-years) of new-onset AF in diabetic patients taking metformin plus DPP4i or other hypoglycemic agents

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

 

New-onset AF

Numbers

Events

Incidence before weighting

Incidence after weighting

HRa

95% CI

P value

DPP4i

16,017

45

0.14 (0.10–0.18)

0.14 (0.12–0.15)*

1.00

(Reference)

Other hypoglycemic agents rather than DPP4i

74,863

386

0.21 (0.19–0.24)

0.21 (0.19–0.23)

1.53

(1.31–1.78)

P < 0.0001

Sulfonylurea

62,216

318

0.20 (0.18–0.23)

0.20 (0.18–0.23)

1.45

(1.24–1.70)

P < 0.0001

Alpha glucosidase inhibitor

5091

24

0.24 (0.14–0.33)

0.23 (0.15–0.32)

1.75

(1.19–2.57)

P = 0.0045

Meglitinide

5164

41

0.38 (0.26–0.49)

0.38 (0.27–0.48)

2.78

(2.05–3.76)

P < 0.0001

TZD

3091

15

0.23 (0.11–0.34)

0.23 (0.12–0.33)

1.68

(1.05–2.69)

P = 0.0307

Insulin

1361

3

0.11 (0.02–0.32)

0.11 (0.03–0.29)

0.79

(0.28–2.26)

P = 0.20

GLP1

5

0

   
  1. There were 2016 patients taking more than two hypoglycemic agents as second-line hypoglycemic agents at the same time
  2. ACEI angiotensin-converting-enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor antagonists, CI confidence interval, DM diabetes mellitus, DPP4i dipeptidyl peptidase-4 inhibitor, GLP-1 glucagon-like peptide-1; PAOD peripheral arterial obstructive disease, TZD thiazolidinedione
  3. aFor other hypoglycemic agents versus DPP-4 inhibitors (reference) after propensity score weighting